During the last session, Rigel Pharmaceuticals (NASDAQ:RIGL)’s traded shares were 2.97 million, with the beta value of the company hitting 1.03. At the end of the trading day, the stock’s price was $1.10, reflecting an intraday loss of -2.22% or -$0.02. The 52-week high for the RIGL share is $1.96, that puts it down -78.18 from that peak though still a striking 35.45% gain since the share price plummeted to a 52-week low of $0.71. The company’s market capitalization is $192.92M, and the average trade volume was 1.43 million shares over the past three months.
Rigel Pharmaceuticals (NASDAQ:RIGL) trade information
Rigel Pharmaceuticals (RIGL) registered a -2.22% downside in the last session and has traded in the green over the past 5 sessions. The stock plummet -2.22% in intraday trading to $1.10, hitting a weekly high. The stock’s 5-day price performance is 4.76%, and it has moved by -22.54% in 30 days. Based on these gigs, the overall price performance for the year is -2.65%.
Rigel Pharmaceuticals (RIGL) estimates and forecasts
Statistics show that Rigel Pharmaceuticals has outperformed its competitors in share price, compared to the industry in which it operates. Rigel Pharmaceuticals (RIGL) shares have gone up 40.94% during the last six months, with a year-to-date growth rate more than the industry average at 64.29% against 10.20. In the rating firms’ projections, revenue will increase 27.50% compared to the previous financial year.
As companies strive to predict their financial trajectories, we turn our attention to the forthcoming financial quarter. Here are the insights gathered from industry analysts. Revenue for the current quarter is expected to be 31.28M as predicted by 5 analyst(s). Meanwhile, a consensus of 5 analyst(s) estimates revenue growth to 33.1M by the end of current fiscal year. As per earnings report from last fiscal year’s results, sales for the corresponding quarters totaled 26.07M and 26.89M respectively. In this case, analysts expect current quarter sales to grow by 20.00% and then jump by 23.10% in the coming quarter.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings grew an estimated 19.96%. While earnings are projected to return 54.12% in 2024.
RIGL Dividends
Rigel Pharmaceuticals is due to release its next quarterly earnings in May. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
